An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies. The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical
Mice have been instrumental in the study of cancer, but like all animal models of human diseases, they have their limitations. For stomach cancer in particular, mice have historically been regarded as quite poor research organisms because rodents rarely develop spontaneous stomach tumors. But results from a new study are about to shake up the paradigm.
Mina Bissell, a distinguished scientist at the Berkeley Lab, has been selected to receive two prestigious awards for her pioneering contributions to breast cancer biology and medicine.
A research team has demonstrated how light-emitting nanoparticles, developed at Berkeley Lab, can be used to see deep in living tissue. Researchers hope they can be made to attach to specific components of cells to serve in an advanced imaging system that can pinpoint even single cancer cells.
A protein called XPG plays a previously unknown and critical role helping to maintain genome stability in human cells. It may also help prevent breast, ovarian, and other cancers associated with defective BRCA genes.
Berkeley Lab researchers have developed the first clinically-relevant mouse model of human breast cancer to successfully express functional estrogen receptor positive adenocarcinomas.
This model should be a powerful tool for testing therapies for aggressive ER+ breast cancers and for studying luminal cancers — the most prevalent and deadliest forms of breast cancer.
Berkeley Lab researchers have developed a new family of nanocarriers, called “3HM,” that meets all the size and stability requirements for effectively delivering therapeutic drugs to the brain for the treatment of a deadly form of cancer known as glioblastoma multiforme.
Berkeley Lab researchers have been awarded $1.3 million for two sets of studies to better understand the health impacts of thirdhand smoke, the noxious residue that clings to virtually all indoor surfaces long after the secondhand smoke from a cigarette has cleared out.
Time-lapse imaging can make complicated processes easier to grasp. Berkeley Lab scientists are using a similar approach to study how cells repair DNA damage. Microscopy images are acquired about every thirty minutes over a span of up to two days, and the resulting sequence of images shows ever-changing hotspots inside cells where DNA is under repair.
Berkeley Lab scientists are developing a cell culture that could help researchers better identify chemicals that increase breast cancer susceptibility. The scientists will grow the culture using adult stem cells obtained from breast tissue. Their test will show if a chemical causes a breakdown in cell-to-cell communication, which is a fundamental defect of cancer.